[go: up one dir, main page]

ES8703520A1 - Procedimiento de preparar particulas que contienen secuencias de aminoacidos y que tienen propiedades inmunogenas - Google Patents

Procedimiento de preparar particulas que contienen secuencias de aminoacidos y que tienen propiedades inmunogenas

Info

Publication number
ES8703520A1
ES8703520A1 ES555124A ES555124A ES8703520A1 ES 8703520 A1 ES8703520 A1 ES 8703520A1 ES 555124 A ES555124 A ES 555124A ES 555124 A ES555124 A ES 555124A ES 8703520 A1 ES8703520 A1 ES 8703520A1
Authority
ES
Spain
Prior art keywords
amino acid
particles
immunogenous
procedure
properties
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
ES555124A
Other languages
English (en)
Other versions
ES555124A0 (es
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut Pasteur
Original Assignee
Institut Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Institut Pasteur filed Critical Institut Pasteur
Publication of ES555124A0 publication Critical patent/ES555124A0/es
Publication of ES8703520A1 publication Critical patent/ES8703520A1/es
Expired legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32622—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

PROCEDIMIENTO DE PREPARAR PARTICULAS QUE CONTIENEN SECUENCIAS DE AMINOACIDOS Y QUE TIENEN PROPIEDADES INMUNOGENAS. COMPRENDE: A) TRANSFORMAR UNA LINEA CELULAR HUMANA O ANIMAL CON UN ADN RECOMBINANTE QUE CONTIENE UNA SECUENCIA DE ADN QUE CODIFICA PARA LA REGION -S Y PRE-S DEL GENOMA DEL VIRUS DE LA HEPATITIS VIRAL, PARA FORMAR UN MICROORGANISMO; B) CULTIVAR AL MICROORGANISMO; Y C) RECOGER LAS PARTICULAS PRODUCIDAS EN EL MEDIO DE CULTIVO DEL HUESPED CELULAR. LA SECUENCIA DE ADN ESTA LOCALMENTE MODIFICADA POR UNA SECUENCIA NUCLEOTIDICA QUE CODIFICA SECUENCIAS EXTRAÑAS EN UNA DE LAS ZONAS DE LA REGION S QUE CORRESPONDEN A LAS REGIONES HIDROFILAS DEL POLIPEPTIDO MAYOR Y CUYA REGION S Y REGION PRE-S ESTAN EN EL INTERIOR DEL ADN RECOMBINANTE, SITUADO BAJO EL CONTROL DIRECTO DE UN PROMOTOR EXOGENO QUE PEMRITE LA INICIACION EFICAZ DE LA TRANSCRIPCION DE LOS GENES.
ES555124A 1985-05-02 1986-05-02 Procedimiento de preparar particulas que contienen secuencias de aminoacidos y que tienen propiedades inmunogenas Expired ES8703520A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR8506708A FR2581394B1 (fr) 1985-05-02 1985-05-02 Particules ayant les proprietes immunogenes de l'antigene hbs et portant un site antigenique etranger aux epitopes portes par l'antigene hbs, vecteurs et cellules animales pour la production de telles particules et compositions contenant de telles particules pour la production de vaccins mixtes

Publications (2)

Publication Number Publication Date
ES555124A0 ES555124A0 (es) 1987-03-01
ES8703520A1 true ES8703520A1 (es) 1987-03-01

Family

ID=9318908

Family Applications (1)

Application Number Title Priority Date Filing Date
ES555124A Expired ES8703520A1 (es) 1985-05-02 1986-05-02 Procedimiento de preparar particulas que contienen secuencias de aminoacidos y que tienen propiedades inmunogenas

Country Status (10)

Country Link
EP (1) EP0201416B1 (es)
JP (2) JPH088869B2 (es)
AT (1) ATE62508T1 (es)
CA (1) CA1282021C (es)
DE (1) DE3678609D1 (es)
DK (1) DK166357C (es)
ES (1) ES8703520A1 (es)
FR (1) FR2581394B1 (es)
GR (1) GR861141B (es)
PT (1) PT82500B (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP56A (en) * 1987-01-30 1989-09-26 Smithkline Biologicals S A Hepatitis B virus surface antigens and hybrid antigehs containing them.
ES2167304T3 (es) * 1987-06-22 2002-05-16 Medeva Holdings Bv Peptido que contiene el antigeno de superficie de la hepatitis b.
FR2635532B1 (fr) * 1988-07-29 1992-05-22 Pasteur Institut Particules hbsag recombinantes hybrides : caracteristiques morphologiques de l'antigene hbsag contenant 1 sequence immunogene induisant des anticorps neutralisants diriges contre hiv ou susceptible d'etre reconnue par de tels anticorps; sequences nucleotidiques codant pour de telles particules; vaccins les contenant
EP0491077A1 (en) * 1990-12-19 1992-06-24 Medeva Holdings B.V. A composition used as a therapeutic agent against chronic viral hepatic diseases
JP4647870B2 (ja) * 1999-11-24 2011-03-09 ノバルティス バクシンズ アンド ダイアグノスティックス，インコーポレーテッド Ｈｂｖ／ｈｃｖウイルス様粒子
US6740323B1 (en) 1999-11-24 2004-05-25 Chiron Corporation HBV/HCV virus-like particle
JP4085231B2 (ja) 2000-02-28 2008-05-14 株式会社ビークル タンパク質中空ナノ粒子とそれを用いた物質運搬体、ならびに細胞への物質導入方法
US7128911B2 (en) 2001-01-19 2006-10-31 Cytos Biotechnology Ag Antigen arrays for treatment of bone disease
US7094409B2 (en) 2001-01-19 2006-08-22 Cytos Biotechnology Ag Antigen arrays for treatment of allergic eosinophilic diseases
EP2196217A1 (en) 2001-09-14 2010-06-16 Cytos Biotechnology AG Packaging of immunostimulatory substances into virus-like particles: method of preparation and use
US7115266B2 (en) 2001-10-05 2006-10-03 Cytos Biotechnology Ag Angiotensin peptide-carrier conjugates and uses thereof
JP2003286199A (ja) * 2002-03-29 2003-10-07 Japan Science & Technology Corp タンパク質中空ナノ粒子を用いる肝臓疾患治療用薬剤
JP2003286198A (ja) * 2002-03-29 2003-10-07 Japan Science & Technology Corp 増殖因子等を提示するタンパク質中空ナノ粒子を用いる治療薬剤
JP2003286189A (ja) * 2002-03-29 2003-10-07 Japan Science & Technology Corp 中空ナノ粒子を形成するタンパク質に疾患治療用の細胞導入物質を融合させた薬剤
KR100632073B1 (ko) * 2002-06-28 2006-10-04 도꾸리쯔교세이호징 가가꾸 기쥬쯔 신꼬 기꼬 시스테인 잔기를 변형한 단백질로 이루어지는 중공 나노입자 및 이를 이용한 약제
JP4509999B2 (ja) * 2003-02-17 2010-07-21 ブルクハルト，ペーター 医薬送達及び抗原提示システムとしてのペプチドナノ粒子
US7537767B2 (en) 2003-03-26 2009-05-26 Cytis Biotechnology Ag Melan-A- carrier conjugates
CN100560719C (zh) 2003-03-26 2009-11-18 赛托斯生物技术公司 Melan-a肽类似物-病毒样颗粒偶联物
EP2766386A1 (en) 2011-10-12 2014-08-20 Alpha-o Peptides AG Self-assembling peptide nanoparticles as vaccines against infection with norovirus
US20150344529A1 (en) 2012-12-25 2015-12-03 The Chemo-Sero-Therapeutic Research Institute Vaccine for hpv infection and/or hepatitis b comprising hpv/hbs chimeric protein as active ingredient
US10279019B2 (en) 2014-02-11 2019-05-07 Stc.Unm PCSK9 peptide vaccine conjugated to a Qbeta carrier and methods of using the same
US20200061172A1 (en) 2017-02-23 2020-02-27 Alpha-O Peptides Ag Self-assembling protein nanoparticles encapsulating immunostimulatory nucleid acids
WO2018172447A1 (en) 2017-03-23 2018-09-27 Alpha-O Peptides Ag Self-assembling protein nanoparticles with built-in six-helix bundle proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4415491A (en) * 1980-01-14 1983-11-15 The Regents Of The University Of California Synthetic vaccine peptide epitomes of hepatitis B surface antigen
FR2532850B1 (fr) * 1982-09-15 1985-12-20 Pasteur Institut Conjugues immunogenes entre un haptene et une molecule porteuse derivee d'une toxine, les vaccins les composant et procede pour leur obtention
US4483793A (en) * 1982-10-04 1984-11-20 The Regents Of The University Of California Dimeric oligopeptides as heptenic epitopic sites for hepatitis
FR2550203B1 (fr) * 1983-08-01 1985-11-22 Anvar Peptides synthetiques immunogenes porteurs d'un epitope caracteristique de l'antigene de surface du virus de l'hepatite b et compositions les contenant
FR2569984B1 (fr) * 1984-09-12 1987-08-14 Anvar Molecule synthetique contenant une pluralite d'epitopes distincts, procede pour son obtention et application a la production de polyvaccins

Also Published As

Publication number Publication date
EP0201416A1 (fr) 1986-11-12
DK166357B (da) 1993-04-13
FR2581394B1 (fr) 1988-08-05
PT82500A (fr) 1986-06-01
PT82500B (pt) 1989-05-12
DK166357C (da) 1993-09-06
FR2581394A1 (fr) 1986-11-07
GR861141B (en) 1986-08-21
ES555124A0 (es) 1987-03-01
DK202586A (da) 1986-11-03
JPH088869B2 (ja) 1996-01-31
JPH08198897A (ja) 1996-08-06
EP0201416B1 (fr) 1991-04-10
ATE62508T1 (de) 1991-04-15
JPS61258000A (ja) 1986-11-15
CA1282021C (fr) 1991-03-26
DE3678609D1 (de) 1991-05-16
DK202586D0 (da) 1986-05-02

Similar Documents

Publication Publication Date Title
ES8703520A1 (es) Procedimiento de preparar particulas que contienen secuencias de aminoacidos y que tienen propiedades inmunogenas
CA2020668A1 (en) Fused or hybrid protein comprising viral antigen and lymphokine
EP0149548A3 (en) Nucleic acid encoding a t-cell antigen receptor polypeptide
ATE352559T1 (de) Verfahren zur verminderung der immunogenität von proteinen
ES2009238A6 (es) Metodo para producir proteinas de mycobacterium tuberculosis y peptidos antigenicos de las mismas.
AU3192889A (en) T cell activation markers
DE3786649D1 (de) Pferde-gamma-interferon.
DE69334350D1 (de) P- Selectin Ligandenprotein
ATE82135T1 (de) Synthetische hepatitis-b-virus-vakzine die tzellen- und b-zellenbestimmer enthalten.
DE69737413D1 (en) Bakterioferritin aus helicobacter pylori
ATE121754T1 (de) Vakzine gegen bordetella.
GR852622B (es)
DE69233245D1 (de) Verfahren zur Herstellung von Peptiden
DE59712235D1 (de) Immunologisch aktive proteine von borrelia burgdorferi, dafür kodierende nukleinsäuren sowie deren verwendung in testkits und als impfstoffe
AU5776799A (en) Modified hcv peptide vaccines
EP0276778A3 (en) High level expression in e. coli of soluble mature hil-1beta and derivatives with altered biological activity
EP0317279A3 (en) Peptides for use in the purification of factor viii
AU1321988A (en) The cloning of malaria-specific dna sequences: isolation of the gene for the 140 kd protein
EP0358938A3 (de) Peptide mit Prourokinase-Sequenzen, Verfahren zu ihrer Herstellung und ihre Verwendung, Antikörper gegen diese Peptide und Mittel enthaltend diese Antikörper zur Bestimmung von Prourokinase

Legal Events

Date Code Title Description
FD1A Patent lapsed

Effective date: 20000201